keyword
MENU ▼
Read by QxMD icon Read
search

COPD eosinophil

keyword
https://www.readbyqxmd.com/read/29331313/predictors-of-exacerbation-risk-and-response-to-budesonide-in-patients-with-chronic-obstructive-pulmonary-disease-a-post-hoc-analysis-of-three-randomised-trials
#1
Mona Bafadhel, Stefan Peterson, Miguel A De Blas, Peter M Calverley, Stephen I Rennard, Kai Richter, Malin Fagerås
BACKGROUND: The peripheral blood eosinophil count might help identify those patients with chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations when taking inhaled corticosteroids (ICS). Previous post-hoc analyses have proposed eosinophil cutoffs that are both arbitrary and limited in evaluating complex interactions of treatment response. We modelled eosinophil count as a continuous variable to determine the characteristics that determine both exacerbation risk and clinical response to ICS in patients with COPD...
January 10, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29331310/blood-eosinophil-counts-as-a-guide-for-copd-treatment-strategies
#2
Nicolas Roche, Maeva Zysman, Pierre-Régis Burgel
No abstract text is available yet for this article.
January 10, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29326334/clinical-and-inflammatory-phenotyping-by-breathomics-in-chronic-airway-diseases-irrespective-of-the-diagnostic-label
#3
Rianne de Vries, Yennece W F Dagelet, Pien Spoor, Erik Snoey, Patrick M C Jak, Paul Brinkman, Erica Dijkers, Simon K Bootsma, Fred Elskamp, Frans H C de Jongh, Eric G Haarman, Johannes C C M In 't Veen, Anke-Hilse Maitland-van der Zee, Peter J Sterk
Asthma and chronic obstructive pulmonary disease (COPD) are complex and overlapping diseases that include inflammatory phenotypes. Novel anti-eosinophilic/anti-neutrophilic strategies demand rapid inflammatory phenotyping, which might be accessible from exhaled breath.Our objective was to capture clinical/inflammatory phenotypes in patients with chronic airway disease using an electronic nose (eNose) in a training and validation set.This was a multicentre cross-sectional study in which exhaled breath from asthma and COPD patients (n=435; training n=321 and validation n=114) was analysed using eNose technology...
January 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/29316890/risk-factors-of-postoperative-pulmonary-complications-in-patients-with-asthma-and-copd
#4
Takanori Numata, Katsutoshi Nakayama, Satoko Fujii, Yoko Yumino, Nayuta Saito, Masahiro Yoshida, Yusuke Kurita, Kenji Kobayashi, Saburo Ito, Hirofumi Utsumi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Hiroshi Wakui, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Yumi Kaneko, Kazuyoshi Kuwano
BACKGROUND: Postoperative pulmonary complications (PPC) in patients with pulmonary diseases remain to be resolved clinical issue. However, most evidence regarding PPC has been established more than 10 years ago. Therefore, it is necessary to evaluate perioperative management using new inhalant drugs in patients with obstructive pulmonary diseases. METHODS: April 2014 through March 2015, 346 adult patients with pulmonary diseases (257 asthma, 89 chronic obstructive pulmonary disease (COPD)) underwent non-pulmonary surgery except cataract surgery in our university hospital...
January 9, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29284904/blood-count-of-eosinophil-polymorphonuclear-leucocytes-and-bronchial-hyperreactivity-in-chronic-obstructive-pulmonary-disease
#5
Vesna Cukic
Introduction: Polymorphonuclear eosinophil leucocytes (eosinophils) are found in increased numbers in the circulation and sputum in asthma patients, usually in relation to the severity of asthma but it is the question whether they have a significant role in the development and level of bronchial hyperreactivity in patients with chronic obstructive pulmonary disease (COPD). Objective: to show the role of the eosinophils in the development and level of BHR in patients with COPD and so in the severity of illness...
October 2017: Medical Archives
https://www.readbyqxmd.com/read/29273668/investigating-fractional-exhaled-nitric-oxide-feno-in-chronic-obstructive-pulmonary-disease-copd-and-asthma-copd-overlap-aco-a-scoping-review-protocol
#6
Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi, Nafiseh Naderi, Miriam Barrecheguren, Abolfazl Dehghan, Jean Bourbeau
INTRODUCTION: During the last decade, many articles have been published, including reviews on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring and identifying eosinophilic airway inflammation, especially in asthma, and evaluating corticosteroid responsiveness. However, the exact role of FeNO in patients with chronic obstructive pulmonary disease (COPD) and its ability to distinguish patients with COPD and those having concomitant asthma, that is, asthma-COPD overlap (ACO) is still unclear and needs to be defined...
December 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/29229474/accuracy-of-a-new-algorithm-to-identify-asthma-copd-overlap-aco-patients-in-a-cohort-of-patients-with-chronic-obstructive-airway-disease
#7
Luis Pérez de Llano, Borja G Cosío, Marc Miravitlles, Vicente Plaza
OBJECTIVES: We aimed to characterize the clinical, functional and inflammatory features of patients diagnosed diagnosed with ACO according to a new algorithm and to compare them with those of other chronic obstructive airway disease (COAD) categories (asthma and COPD). METHODS: ACO was diagnosed in a cohort of COAD patients in those patients with COPD who were either diagnosed with current asthma or showed significant blood eosinophilia (≥300cells/μl) and/or a very positive bronchodilator response (>400ml and >15% in FEV1)...
December 8, 2017: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/29227024/blood-biomarkers-as-predictors-of-long-term-mortality-in-copd
#8
Angelico Mendy, Erick Forno, Theophile Niyonsenga, Janvier Gasana
BACKGROUND: Blood biomarkers are easily accessible and might reflect chronic obstructive pulmonary disease (COPD) activity. AIM: To determine whether a panel of blood biomarkers (C-reactive protein [CRP], neutrophils, eosinophils, albumin and vitamin D) could predict mortality in COPD. METHODS: we analyzed data from 431 COPD participants to the 2007-2010 National Health and Nutrition Examination Surveys who were followed for a median time of 36 months...
December 11, 2017: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/29223347/-a-predictive-bacterial-infection-score-according-to-eosinophil-level-an-observational-study
#9
B Bouldoires, H Gil, T Soumagne, S Humbert, N Meaux Ruault, N Magy Bertrand
INTRODUCTION: Several studies have shown that eosinopenia less than 0.04g/L is a marker of bacterial infection in the presence of unexplained inflammatory syndrome. The aim of our study was to test this hypothesis and to propose a predictive score for bacterial infection (score CIBLE, C reactive protein, bacterial infections, levels of leucocytes and eosinophils). PATIENTS AND METHODS: This was a single-center observational study of patients admitted to an internal medicine department in the year 2015 and presenting with an inflammatory biological syndrome...
December 6, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29206629/biological-effects-of-p38-mapk-inhibitor-losmapimod-does-not-translate-to-clinical-benefits-in-copd
#10
Steven Pascoe, Maria Costa, Joanna Marks-Konczalik, Elizabeth McKie, Shuying Yang, Pablo Saez Scherbovsky
RATIONALE: p38 mitogen-activated protein kinase (MAPK) expression is increased in chronic inflammatory disease. Losmapimod, a p38 MAPK inhibitor, has been developed as a potential anti-inflammatory therapy in COPD. OBJECTIVES: To evaluate the effect of losmapimod in reducing exacerbations in subjects with moderate-to-severe COPD. METHODS: In this double-blind, parallel-group study, subjects at risk of COPD exacerbations and ?2% blood eosinophils at screening, were randomized 1:1 to losmapimod 15 mg or placebo (variable treatment duration: 26-52 weeks)...
September 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29206476/systemic-markers-of-adaptive-and-innate-immunity-are-associated-with-copd-severity-and-spirometric-disease-progression
#11
Eitan Halper-Stromberg, Jeong H Yun, Margaret M Parker, Ruth Tal Singer, Amit Gaggar, Edwin K Silverman, Sonia Leach, Russell P Bowler, Peter J Castaldi
The progression of chronic obstructive pulmonary disease (COPD) is associated with marked alterations in circulating immune cell populations, but no studies have characterized alterations in these cell types across the full spectrum of lung function impairment in current and former smokers. In 6,299 subjects from the COPDGene and ECLIPSE studies, we related Coulter blood counts and proportions to cross-sectional FEV1 adjusting for current smoking status. We also related cell count measures to three-year change in FEV1 in ECLIPSE subjects...
December 5, 2017: American Journal of Respiratory Cell and Molecular Biology
https://www.readbyqxmd.com/read/29200843/eosinophilic-and-non-eosinophilic-copd-patients-with-chronic-respiratory-failure-neutrophil-to-lymphocyte-ratio-as-an-exacerbation-marker
#12
Eylem Acartürk Tunçay, Zuhal Karakurt, Emine Aksoy, Cuneyt Saltürk, Sinem Gungor, Nezihe Ciftaslan, İlim Irmak, Dilek Yavuz, Birsen Ocakli, Nalan Adıgüzel
Aim: Increased dyspnea, sputum volume, and purulence are subjective symptoms in COPD patients. To diagnose COPD exacerbations with chronic respiratory failure (CRF) and to assess the requirement for antibiotic treatment, physicians require more objective criteria. We aimed to investigate whether neutrophil-to-lymphocyte ratio (NLR) can be used as an infectious exacerbation marker in COPD patients with CRF. Patients and methods: This retrospective cross-sectional study was performed in the intensive care outpatient clinic of a tertiary training hospital between 2014 and 2015...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29167308/peripheral-eosinophil-count-as-a-biomarker-for-the-management-of-copd-not-there-yet
#13
EDITORIAL
Klaus F Rabe, Bianca Beghé, Leonardo M Fabbri
No abstract text is available yet for this article.
November 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/29167301/prevalence-of-persistent-blood-eosinophilia-relation-to-outcomes-in-patients-with-copd
#14
Ciro Casanova, Bartolome R Celli, Juan P de-Torres, Cristina Martínez-Gonzalez, Borja G Cosio, Victor Pinto-Plata, Pilar de Lucas-Ramos, Miguel Divo, Antonia Fuster, Germán Peces-Barba, Myriam Calle-Rubio, Ingrid Solanes, Ramón Aguero, Nuria Feu-Collado, Inmaculada Alfageme, Alfredo De Diego, Amparo Romero, Eva Balcells, Antonia Llunell, Juan B Galdiz, Margarita Marin, Amalia Moreno, Carlos Cabrera, Rafael Golpe, Celia Lacarcel, Joan B Soriano, José Luis López-Campos, Juan J Soler-Cataluña, José M Marin
The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (≥300 cells·μL-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis...
November 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/29158761/eosinophilic-copd-a-separate-disease-phenotype-warranting-specific-treatment
#15
Leo Koenderman
No abstract text is available yet for this article.
2017: Tanaffos
https://www.readbyqxmd.com/read/29158758/eosinophilic-copd-a-separate-disease-phenotype-warranting-specific-treatment
#16
Leo Koenderman
No abstract text is available yet for this article.
2017: Tanaffos
https://www.readbyqxmd.com/read/29153881/relationship-of-blood-eosinophil-count-to-exacerbations-in-chronic-obstructive-pulmonary-disease
#17
Robert S Zeiger, Trung N Tran, Rebecca K Butler, Michael Schatz, Qiaowu Li, Deepak B Khatry, Ubaldo Martin, Aniket A Kawatkar, Wansu Chen
BACKGROUND: Eosinophilic airway inflammation characterizes a chronic obstructive pulmonary disease (COPD) phenotype that requires more study. OBJECTIVE: To investigate the relationship of blood eosinophil count to exacerbations in COPD. METHODS: Using administrative pharmacy and health care utilization data from 2009 to 2012, we retrospectively identified patients 40 years or older with a COPD diagnosis, postbronchodilator FEV1/forced vital capacity ratio of less than 0...
November 15, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29146301/association-of-sputum-and-blood-eosinophil-concentrations-with-clinical-measures-of-copd-severity-an-analysis-of-the-spiromics-cohort
#18
Annette T Hastie, Fernando J Martinez, Jeffrey L Curtis, Claire M Doerschuk, Nadia N Hansel, Stephanie Christenson, Nirupama Putcha, Victor E Ortega, Xingnan Li, R Graham Barr, Elizabeth E Carretta, David J Couper, Christopher B Cooper, Eric A Hoffman, Richard E Kanner, Eric Kleerup, Wanda K O'Neal, Richard Paine, Stephen P Peters, Neil E Alexis, Prescott G Woodruff, MeiLan K Han, Deborah A Meyers, Eugene R Bleecker
BACKGROUND: Increased concentrations of eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associated with increased frequency of exacerbations, reduced lung function, and corticosteroid responsiveness. We aimed to assess whether high eosinophil concentrations in either sputum or blood are associated with a severe COPD phenotype, including greater exacerbation frequency, and whether blood eosinophils are predictive of sputum eosinophils. METHODS: We did a multicentre observational study analysing comprehensive baseline data from SPIROMICS in patients with COPD aged 40-80 years who had a smoking history of at least 20 pack-years, recruited from six clinical sites and additional subsites in the USA between Nov 12, 2010, and April 21, 2015...
December 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29146300/eosinophils-in-copd-are-we-nearly-there-yet
#19
Mona Bafadhel
No abstract text is available yet for this article.
November 13, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29140725/reply-to-the-significance-of-eosinophilic-inflammation-in-copd
#20
Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, Felix J F Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, Jadwiga A Wedzicha
No abstract text is available yet for this article.
November 15, 2017: American Journal of Respiratory and Critical Care Medicine
keyword
keyword
100321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"